PROLONGED RESPONSE TO THIRD-LINE TREATMENT WITH COMBINATION CCNU/TMZ IN AN MGMT METHYLATED IDH-WILDTYPE GLIOBLASTOMA

被引：0

作者：

Pan, Peter ^{[1
]}

Haggiagi, Aya ^{[2
]}

Iwamoto, Fabio ^{[3
]}

机构：

[1] Columbia Univ, New York, NY USA

[2] Columbia Univ, New York Presbyterian Hosp, Irving Med Ctr, New York, NY USA

[3] New York Presbyterian Columbia Univ, Med Ctr, Div Neurooncol, New York, NY USA

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BIOM-12

引用

页码：6 / 6

页数：1

共 13 条

[1] Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma
Funakoshi, Yusuke
Hata, Nobuhiro
Takigawa, Kosuke
Arita, Hideyuki
Kuga, Daisuke
Hatae, Ryusuke
Sangatsuda, Yuhei
Fujioka, Yutaka
Sako, Aki
Umehara, Toru
Yoshitake, Tadamasa
Togao, Osamu
Hiwatashi, Akio
Yoshimoto, Koji
Iwaki, Toru
Mizoguchi, Masahiro
[J]. CANCER MEDICINE, 2021, 10 (10): : 3177 - 3187
[2] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF CCNU AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Cacilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
[J]. NEURO-ONCOLOGY, 2022, 24 : 74 - 74
[3] First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Caecilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
[J]. NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
[4] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
Lazaridis, L.
Schmidt, T.
Agkatsev, S.
Blau, T.
Spille, D.
Heider, S.
Schulz, T.
Bumes, E.
Oster, C.
Feldheim, J.
Stummer, W.
Kessler, A.
Seidel, C.
Hau, P.
Sure, U.
Keyvani, K.
Herrlinger, U.
Kleinschnitz, C.
Stuschke, M.
Herrmann, K.
Deuschl, C.
Hattingen, E.
Scheffler, B.
Kebir, S.
Glas, M.
[J]. NEURO-ONCOLOGY, 2022, 24
[5] PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial
Herrlinger, Ulrich
Tzaridis, Theophilos
Mack, Frederic
Steinbach, Joachim
Schlegel, Uwe
Sabel, Michael
Hau, Peter
Kortman, Rolf-Dieter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Schnell, Oliver
Baehr, Oliver
Uhl, Martin
Tabatabai, Ghazaleh
Ringel, Florian
Schmidt-Graf, Friederike
Brehmer, Stefanie
Weyerbrock, Astrid
Bullinger, Lars
Vajkoczy, Peter
Vatter, Hartmut
Schaefer, Niklas
Kebir, Sied
Weller, Johannes
Stummer, Walter
Simon, Matthias
Keil, Vera
Nelles, Michael
Fimmers, Rolf
Pietsch, Torsten
Hattingen, Elke
Coch, Christoph
Glas, Martin
[J]. NEURO-ONCOLOGY, 2017, 19 : 13 - 14
[6] QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
Weller, Johannes
Tzaridis, Theophilos
Steinbach, Joachim
Schlegel, Uwe
Hau, Peter
Krex, Dietmar
Grauer, Oliver
Goldbrunner, Roland
Baehr, Oliver
Uhl, Martin
Seidel, Clemens
Tabatabai, Ghazaleh
Bullinger, Lars
Galldiks, Norbert
Schaub, Christina
Stummer, Walter
Simon, Matthias
Fimmers, Rolf
Matthias, Schmid
Coch, Christoph
Glas, Martin
Herrlinger, Ulrich
Schaefer, Niklas
[J]. NEURO-ONCOLOGY, 2018, 20 : 218 - 219
[7] Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma
Seidel, Clemens
Kortmann, Rolf-Dieter
[J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (09) : 855 - 856
[8] REGORAFENIB IN COMBINATION WITH TEMOZOLOMIDE WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED MGMT-METHYLATED, IDH WILDTYPE GLIOBLASTOMA: A PHASE I DOSE-FINDING STUDY (REGOMA-2)
Padovan, Marta
De Salvo, Gian Luca
D'Avolio, Antonio
Caccese, Mario
Zagonel, Vittorina
Lombardi, Giuseppe
[J]. NEURO-ONCOLOGY, 2022, 24 : 73 - 73
[9] Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
Zhicong Li
Adrien Holzgreve
Lena M. Unterrainer
Viktoria C. Ruf
Stefanie Quach
Laura M. Bartos
Bogdana Suchorska
Maximilian Niyazi
Vera Wenter
Jochen Herms
Peter Bartenstein
Joerg-Christian Tonn
Marcus Unterrainer
Nathalie L. Albert
Lena Kaiser
[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 535 - 545
[10] Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH-wildtype glioblastoma
Li, Zhicong
Holzgreve, Adrien
Unterrainer, Lena M.
Ruf, Viktoria C.
Quach, Stefanie
Bartos, Laura M.
Suchorska, Bogdana
Niyazi, Maximilian
Wenter, Vera
Herms, Jochen
Bartenstein, Peter
Tonn, Joerg-Christian
Unterrainer, Marcus
Albert, Nathalie L.
Kaiser, Lena
[J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (02) : 535 - 545

← 1 2 →